7/29/2020, 7:40 AM (Source: TeleTrader)
more TeleTrader news


Chart for: Sanofi SA

Sanofi EPS jump to €6.07 in Q2

Sanofi S.A. reported on Wednesday that its IFRS earnings per share (EPS) for the second quarter of 2020 stood at €6.07, jumping 350% from the last quarter. IFRS net income rose to €7.6 billion. Meanwhile, business EPS rose 3.2% to €1.28.

The French pharmaceutical giant's IFRS net sales were €8,207million, down 4.9% on a reported basis. Sanofi now expects 2020 business EPS to grow between 6%. The currency impact on 2020 business EPS is estimated to be between -3% to -4%. First-half Company sales reached €17,180 million, up 0.9% on a reported basis.

CEO Paul Hudson said: "I'm proud of what the team delivered in the second quarter. Even with some headwinds from the COVID-19 pandemic, we achieved business EPS growth supported by continued outstanding sales from Dupixent, a focus on efficiency and smart spending, and the commitment of our people to patients and our strategic priorities. We also met important regulatory milestones, forged new R&D alliances, and accelerated our efforts to develop potential COVID-19 vaccines. With four new appointments, the management team at Sanofi is now complete and together we are focused on delivering our full-year 2020 guidance."

Breaking the News / TF